Ian J. Kulac

979 total citations · 1 hit paper
18 papers, 232 citations indexed

About

Ian J. Kulac is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nephrology. According to data from OpenAlex, Ian J. Kulac has authored 18 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 11 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Nephrology. Recurrent topics in Ian J. Kulac's work include Heart Failure Treatment and Management (12 papers), Cardiovascular Function and Risk Factors (8 papers) and Hormonal Regulation and Hypertension (6 papers). Ian J. Kulac is often cited by papers focused on Heart Failure Treatment and Management (12 papers), Cardiovascular Function and Risk Factors (8 papers) and Hormonal Regulation and Hypertension (6 papers). Ian J. Kulac collaborates with scholars based in United States, United Kingdom and Singapore. Ian J. Kulac's co-authors include Brian Claggett, Scott D. Solomon, John J.V. McMurray, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Zi Michael Miao, Sanjiv J. Shah and Adrian F. Hernandez and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Journal of the American Society of Nephrology.

In The Last Decade

Ian J. Kulac

15 papers receiving 226 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial

2025 35 citations Alexander Peikert, Muthiah Vaduganathan et al. European Heart Journal profile →

Peers

Countries citing papers authored by Ian J. Kulac

Since Specialization

Citations

This map shows the geographic impact of Ian J. Kulac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian J. Kulac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian J. Kulac more than expected).

Fields of papers citing papers by Ian J. Kulac

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian J. Kulac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian J. Kulac. The network helps show where Ian J. Kulac may publish in the future.

Co-authorship network of co-authors of Ian J. Kulac

This figure shows the co-authorship network connecting the top 25 collaborators of Ian J. Kulac. A scholar is included among the top collaborators of Ian J. Kulac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian J. Kulac. Ian J. Kulac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial 2026 ·European Journal of Heart Failure ·(unknown), (unknown), Ian J. Kulac, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), A W Voors, (unknown), (unknown), Andrea Lage, (unknown), Yoriko De Sanctis, Andrea Glasauer, (unknown), (unknown), (unknown)	0
2	Interplay of Serum Potassium and Kidney Function with Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Findings from FINEARTS-HF 2025 ·European Journal of Heart Failure ·João Pedro Ferreira, (unknown), Brian Claggett, Ian J. Kulac, John W. Ostrominski, Akshay S. Desai, Pardeep S. Jhund, (unknown), Michele Senni, (unknown), Adriaan A. Voors, B. Pitt, Katja Rohwedder, Meike Brinker, Patrick Schloemer, John J.V. McMurray, Scott Solomon, Faïez Zannad	0
3	Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial breakdown → 2025 ·European Heart Journal ·Alexander Peikert, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Sheldon E. Litwin, Michael R. Zile, Akshay S. Desai, Pardeep S. Jhund, Jawad H. Butt, Carolyn S.P. Lam, Felipe Martínez‐Pastor, Dirk J. van Veldhuisen, Faı̈ez Zannad, Jean L. Rouleau, Marty Lefkowitz, John J.V. McMurray, Scott D. Solomon, Milton Packer	35
4	Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial 2025 ·European Heart Journal ·Martin S. Maron, Juan R. Gimeno, Josef Veselka, Roberto Barriales‐Villa, Brian Claggett, Caroline Coats, Sheila M. Hegde, James L. Januzzi, Ian J. Kulac, Ahmad Masri, Michael E. Nassif, John A. Spertus, Daniel Jacoby, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Amy Wohltman, Iacopo Olivotto	3
5	Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure 2024 ·Journal of Cardiac Failure ·John W. Ostrominski, Rahul Aggarwal, Brian Claggett, Ian J. Kulac, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, James Lay‐Flurrie, Prabhakar Viswanathan, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan	4
6	Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials 2024 ·Journal of the American Heart Association ·Ankeet S. Bhatt, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Inder S. Anand, Akshay S. Desai, James C. Fang, Adrian F. Hernandez, Pardeep S. Jhund, Mikhail Kosiborod, Marc S. Sabatine, Sanjiv J. Shah, Orly Vardeny, John J.V. McMurray, Scott D. Solomon, Thomas A. Gaziano	5
7	Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure 2024 ·Circulation ·Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Zi Michael Miao, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, James Lay‐Flurrie, Prabhakar Viswanathan, Markus F. Scheerer, Andrea Lage, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Bertram Pitt, John J.V. McMurray, Scott D. Solomon	25
8	Finerenone in Patients With a Recent Worsening Heart Failure Event 2024 ·Journal of the American College of Cardiology ·Akshay S. Desai, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Pardeep S. Jhund, Jonathan W. Cunningham, Maria Borentain, James Lay‐Flurrie, Prabhakar Viswanathan, Katja Rohwedder, Flaviana Amarante, (unknown), Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, (unknown), Mikhail Kosiborod, John J.V. McMurray, Scott D. Solomon	9
9	Effect of Dapagliflozin in Patients with Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Background Glucose-Lowering Therapy: A Pre-Specified Analysis of the DELIVER Trial 2024 ·European Journal of Heart Failure ·Mats Christian Højbjerg Lassen, John W. Ostrominski, Silvio E. Inzucchi, Brian Claggett, Ian J. Kulac, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Akshay S. Desai, (unknown), Anna Maria Langkilde, Kieran F. Docherty, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan	5
10	Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial 2024 ·Journal of the American Society of Nephrology ·Finnian R. Mc Causland, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Robert M. Perkins, Markus F. Scheerer, Patrick Schloemer, (unknown), Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, (unknown), John J.V. McMurray, Scott D. Solomon	1
11	Finerenone and Kidney Outcomes in Patients With Heart Failure 2024 ·Journal of the American College of Cardiology ·Finnian R. Mc Causland, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, (unknown), Markus F. Scheerer, Patrick Schloemer, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Bertram Pitt, John J.V. McMurray, Scott D. Solomon	21
12	Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF 2023 ·European Heart Journal ·Muthiah Vaduganathan, Robert J. Mentz, Brian Claggett, Zi Michael Miao, Ian J. Kulac, Jonathan H. Ward, Adrian F. Hernandez, David A. Morrow, Randall C. Starling, Eric J. Velazquez, Kristin Williamson, Akshay S. Desai, Shelley Zieroth, Martin Lefkowitz, John J.V. McMurray, Eugene Braunwald, Scott D. Solomon	56
13	Validity of the Yellow Flag Risk Form in People Treated for Low Back Pain with Mechanical Diagnosis and Therapy and the Pain Mechanism Classification System 2023 ·Ronald Schenk, (unknown), Michael D. Ross, Ian J. Kulac, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas F. Coleman, (unknown), Dave A. May, (unknown), (unknown), (unknown)	0
14	Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan 2023 ·European Journal of Heart Failure ·Peder L. Myhre, Yuxi Liu, Ian J. Kulac, Brian Claggett, Margaret F. Prescott, G. Michael Felker, Javed Butler, Ileana L. Piña, Jean L. Rouleau, Michael R. Zile, John J.V. McMurray, Jonathan H. Ward, Scott D. Solomon, James L. Januzzi	6
15	Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials 2023 ·European Journal of Heart Failure ·Ankeet S. Bhatt, Mikhail Kosiborod, Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Ian J. Kulac, Carolyn S.P. Lam, Adrian F. Hernandez, Felipe A. Martínez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon	12
16	Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis 2023 ·Journal of Cardiac Failure ·Ahmad Masri, Mathew S. Maurer, Brian Claggett, Ian J. Kulac, Márcia Waddington‐Cruz, Isabel Conceição, Markus Weiler, John L. Berk, Morie A. Gertz, Julian D. Gillmore, Stephen Rush, Jersey Chen, Wunan Zhou, (unknown), Jason M. Duran, Sotirios Tsimikas, Scott D. Solomon	16
17	Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status 2023 ·JACC Heart Failure ·Alexander Peikert, Parag Goyal, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Zi Michael Miao, Orly Vardeny, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon	13
18	Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF 2023 ·JACC Heart Failure ·Alexander Peikert, Bradley A. Bart, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon, Orly Vardeny	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact